Drug intelligence / Profile preview

PB-008

Development stage: Preclinical
Lead developer: Polpharma Biologics
Modality: Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules

Overview

PB-008 is a biosimilar drug candidate developed by Polpharma Biologics. It is classified as an antineoplastic (anti-cancer) agent and is being investigated for the treatment of cancers (neoplasms). The specific reference product for this biosimilar has not been publicly disclosed, and its precise mechanism of action remains undefined in available sources. As of the latest updates, there are no reported clinical development phases beyond preclinical or pending status, and no recent progress has been noted in clinical trials or approvals[1][3].

Beyond the preview

Go deeper on PB-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB-008.

Explore the full profile